A Phase 3 interventional study of Vitamin D3 50,000 IU and Vitamin C/Zinc in Covid19, sponsored by The Canadian College of Naturopathic Medicine. Terminated at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by The Canadian College of Naturopathic Medicine · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing cholecalciferol in COVID-19 — none open to participants now, 1 under way, 1 of them phase 3. Cholecalciferol · COVID-19.
Among the 17 studies testing cholecalciferol in COVID-19, this one is the 8th largest by enrollment, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 10th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →None of the 17 studies testing cholecalciferol in COVID-19 is open now. The open studies under COVID-19, anywhere →
Cholecalciferol: first FDA approval 2000 (INFUVITE ADULT), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 80 across the 17 interventional studies. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 17 has an industry lead sponsor. The 10 most frequent:
The Canadian College of Naturopathic Medicine is the lead sponsor of 19 studies on the registry; 1 is open to participants now.
The Canadian College of Naturopathic Medicine has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
1 of the studies testing cholecalciferol in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03188796Phase 3Medical University of GrazThe VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing cholecalciferol in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a double blind, placebo controlled, phase III randomized controlled trial evaluating the effects of the dietary supplements vitamin C, vitamin D, vitamin K, and zinc versus placebo on the overall health, symptom severity, and symptom duration of outpatients diagnosed with SARS-CoV-2.
This study proposed is a double-blind, placebo-controlled, phase III randomized controlled trial powered to detect meaningful differences in the overall health and symptom severity of people with COVID-19 between the treatment and control arms. Eligible participants will be randomly assigned, using a web randomization system, in a ratio of 1:1 to one of the following groups: (1) nutrient therapy with vitamin D, vitamin C, vitamin K2, and zinc or (2) placebo. Total trial duration will be 12 weeks. Nutrients or placebo will be given for a period of 21 days following enrolment and randomization. Total trial duration will be 12 weeks. Adverse events will be collected during the treatment phase plus one additional week (maximum 4 weeks).
With respect to the primary outcome of participant-reported overall health, power calculations were conducted based on between-group differences at a single time point (21 days) and Cohen's guideline for a small effect size of 0.3. A sample size of 176 (88 per arm) provides 80% power to detect a difference at an α of 0.05. To account for an approximate 10-15% lost to follow-up we will enrol 200 participants (100 per arm).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Specific Product: Vitamin D3 50,000 IU Formulation: Capsule. Each capsule will contain 500 mg (50,000 units) cholecalciferol (vitamin D3) Dose: One capsule on day 1 of the intervention period Specific Product: Vitamin K2/D Formulation: Liquid. Each 0.0285 mL drop contains 30 mcg menaquinone-7 (MK-7, vitamin K2) and 3.125 mcg (125 units) cholecalciferol (vitamin D3). Dose: 0.114 mL (four drops) twice daily for 21 days totalling 240mcg MK-7 and 1,000 units cholecalciferol per day. Specific Product: Vitamin C/Zinc Formulation: Capsule. Each capsule will contain 666 mg ascorbic acid (vitamin C) and 8.3 mg of zinc acetate Dose: Three capsules three times daily for 21 days totalling 6 g ascorbic acid and 75 mg zinc acetate per day.
Drug: Vitamin D3 50,000 IU · Dietary Supplement: Vitamin C/Zinc · Dietary Supplement: Vitamin K2/D
Specific Product: Vitamin D3 50,000 IU Placebo Equivalent: microcrystalline cellulose capsule, 350 mg Specific Product: Vitamin K2/D Placebo Equivalent: Medium chain triglyceride oil Specific Product: Vitamin C/Zinc Placebo Equivalent: microcrystalline cellulose capsule, 350 mg
Other: Microcrystalline Cellulose Capsule · Other: Medium Chain Triglyceride Oil
This is a loading dose of Vitamin D. Vitamin D (cholecalciferol \[vitamin D3\]) is a fat-soluble vitamin that is synthesized following ultraviolet radiation to the skin, naturally occurs in a few dietary sources and is available as a dietary supplement.
Also known as: Cholecalciferol
Drug pages: Ascorbic AcidStudies of Ascorbic AcidAscorbic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ZincStudies of ZincZinc pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
This is a combination of Vitamin C and Zinc. Vitamin C (ascorbic acid, ascorbate) is a water-soluble vitamin that naturally occurs in many foods and is sold as a dietary supplement. It is required for the functioning of several enzymes and is important for the immune system. Zinc is one of the most abundant essential trace elements in the human body and is required for the function of several hundred enzymes and transcription factors.
Drug page: Vitamin K 2Studies of Vitamin K 2Vitamin K 2 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
This is a combination of Vitamin K2 (menaquinone-7) and vitamin D. Vitamin K (menaquinone-7 \[vitamin K2\]) is a fat-soluble vitamin found in foods and sold as a dietary supplement. Vitamin K plays a large role in synthesizing coagulation factors in the blood, and vitamin K deficiency has been associated with uncontrolled bleeding. Vitamin K1 (phylloquinone) is an alternate form of vitamin K found in foods and supplements; however, vitamin K2 has a better absorption profile50 and additionally plays a role in bone metabolism controlling the binding of calcium, especially in older adults, where it attenuates the rate of bone loss
Placebo equivalent of Vitamin C/Zinc and Vitamin D3.
Placebo equivalent of Vitamin K2/D
Participant-reported Overall Health
Measured using the EuroQol Visual Assessment Scale (EQ-VAS). Scores each day range from 0 (worst health imaginable) and 100 (best health imaginable). Scores summed over a 21-day period for a total range of 0-2100.
Time frame: During the intervention period (Daily for 21 days)
Effect of COVID-19 on the Health Status of Participants
Measured using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Scores are converted into a unique health state. Health states are converted to an index value between 0 and 1, where 1 is considered the best possible health and 0 is the worst possible health.
Time frame: Baseline plus weeks 1, 2, 3, 4, 8, and 12
Symptom Severity of Common COVID-19 Symptoms
Measured using an internally-developed questionnaire. Includes fever, cough, shortness of breath, fatigue, headache, myalgia/arthralgia, nausea, vomiting, diarrhea, congestion, loss of taste, and loss of smell. Scores range from 0-3 for each symptom, totaling 0-42 for each day. 0 = no symptom, 1 = mild symptom, 2 = moderate symptom, 3 = severe symptom. Scores converted into a number out of 100 and summed over 21 days for a range of 0-2100 where a higher score indicates a higher symptom severity (i.e., a worse outcome).
Time frame: During the intervention period (Daily for 21 days)
Total Symptom Duration
Measured as the time to a complete reduction of symptoms with no relapses (i.e., a 0 in all categories on the symptom questionnaire).
Time frame: During the intervention period (21 days)
Incidence of Delayed Return to Usual Health
Measured by the number of people experiencing "ongoing symptomatic COVID-19" (symptoms persisting between 4 and 12 weeks) and the number of people experiencing "post-COVID-19 syndrome" (symptoms persisting at least 12 weeks)
Time frame: 12 weeks
Number of Participants With a Hospital Visit or Admission
Includes ER visits, acute care admissions, and ICU admissions
Time frame: 12 weeks
Participants were enrolled from outpatient COVID-19 test centres associated with The Ottawa Hospital. The primary site for enrolment and coordination of the study was The Centre for Health Innovation, Ottawa, Canada with support from the Ottawa Hospital Research Institute.
| Milestone | Treatment | Control |
|---|---|---|
| Started | 44 | 46 |
| Treated | 42 | 44 |
| Completed | 36 | 31 |
| Not completed | 8 | 15 |
| Withdrew: Withdrawal by subject | 5 | 8 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 5 |
Measured using the EuroQol Visual Assessment Scale (EQ-VAS). Scores each day range from 0 (worst health imaginable) and 100 (best health imaginable). Scores summed over a 21-day period for a total range of 0-2100.
| score on a scale | Treatment | Control |
|---|---|---|
| Participant-reported Overall Health | 1790 ± 226.6 | 1752.6 ± 220.7 |
Measured using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Scores are converted into a unique health state. Health states are converted to an index value between 0 and 1, where 1 is considered the best possible health and 0 is the worst possible health.
| score on a scale | Treatment | Control |
|---|---|---|
| Baseline | 0.88 ± 0.1 | 0.88 ± 0.12 |
| Week 1 | 0.95 ± 0.08 | 0.93 ± 0.1 |
| Week 2 | 0.95 ± 0.07 | 0.94 ± 0.09 |
| Week 3 | 0.94 ± 0.08 | 0.91 ± 0.1 |
| Week 4 | 0.96 ± 0.08 | 0.97 ± 0.05 |
| Week 8 | 0.95 ± 0.08 | 0.95 ± 0.09 |
| Week 12 | 0.96 ± 0.07 | 0.96 ± 0.07 |
Measured using an internally-developed questionnaire. Includes fever, cough, shortness of breath, fatigue, headache, myalgia/arthralgia, nausea, vomiting, diarrhea, congestion, loss of taste, and loss of smell. Scores range from 0-3 for each symptom, totaling 0-42 for each day. 0 = no symptom, 1 = mild symptom, 2 = moderate symptom, 3 = severe symptom. Scores converted into a number out of 100 and summed over 21 days for a range of 0-2100 where a higher score indicates a higher symptom severity (i.e., a worse outcome).
| score on a scale | Treatment | Control |
|---|---|---|
| Symptom Severity of Common COVID-19 Symptoms | 166.3 ± 92.3 | 192.9 ± 153.6 |
Measured as the time to a complete reduction of symptoms with no relapses (i.e., a 0 in all categories on the symptom questionnaire).
| Days | Treatment | Control |
|---|---|---|
| Total Symptom Duration | 13.0 (0 to 21) | 12.5 (0 to 21) |
Measured by the number of people experiencing "ongoing symptomatic COVID-19" (symptoms persisting between 4 and 12 weeks) and the number of people experiencing "post-COVID-19 syndrome" (symptoms persisting at least 12 weeks)
| Participants | Treatment | Control |
|---|---|---|
| Ongoing Symptomatic COVID-19 | 6 | 5 |
| Post COVID-19 Syndrome | 3 | 3 |
Includes ER visits, acute care admissions, and ICU admissions
| Participants | Treatment | Control |
|---|---|---|
| Emergency Room Visits | 2 | 4 |
| Acute Care Admissions | 0 | 0 |
| Intensive Care Unit Admissions | 0 | 0 |
Collected over During the intervention period (21 days) plus 1 additional week (4 weeks total). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment | 0/44 (0%) | 0/44 (0%) | 16/44 (36.4%) |
| Control | 0/46 (0%) | 1/46 (2.2%) | 6/46 (13%) |
| Event | Treatment | Control |
|---|---|---|
| Ectopic PregnancyPregnancy, puerperium and perinatal conditions | 0/44 | 1/46 |
| Event | Treatment | Control |
|---|---|---|
| NauseaGastrointestinal disorders | 8/44 | 1/46 |
| Abdominal PainGastrointestinal disorders | 2/44 | 2/46 |
| BloatingGastrointestinal disorders | 2/44 | 0/46 |
| HeartburnGastrointestinal disorders | 1/44 | 0/46 |
| Jaw PainMusculoskeletal and connective tissue disorders | 1/44 | 0/46 |
| DyspepsiaGastrointestinal disorders | 1/44 | 0/46 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/44 | 0/46 |
| HeadacheNervous system disorders | 0/44 | 1/46 |
| VomitingGastrointestinal disorders | 0/44 | 1/46 |
| DiarrheaGastrointestinal disorders | 0/44 | 1/46 |
Participants only included if they began study treatments.
| Age, Continuous(years) | Treatment | Control | Total |
|---|---|---|---|
| Mean | 38 ± 12.7 | 39.9 ± 14.9 | 38.9 ± 13.8 |
| Sex: Female, Male(Participants) | Treatment | Control | Total |
|---|---|---|---|
| Female | 17 | 26 | 43 |
| Male | 25 | 18 | 43 |
| Race/Ethnicity, Customized(Participants) | Treatment | Control | Total |
|---|---|---|---|
| Black | 1 | 2 | 3 |
| White | 37 | 34 | 71 |
| Latin American | 1 | 0 | 1 |
| Asian (South) | 0 | 1 | 1 |
| Asian (Southeast) | 1 | 1 | 2 |
| Asian (East) | 0 | 2 | 2 |
| Middle Eastern | 2 | 0 | 2 |
| Vaccination Status(Participants) | Treatment | Control | Total |
|---|---|---|---|
| Received First Dose | 41 | 42 | 83 |
| Received Second Dose | 41 | 42 | 83 |
| Received Third Dose | 37 | 30 | 67 |
| Unvaccinated | 1 | 2 | 3 |
| Comorbidities(Participants) | Treatment | Control | Total |
|---|---|---|---|
| Hypertension | 3 | 1 | 4 |
| Diabetes | 0 | 2 | 2 |
| Coronary Artery Disease | 0 | 0 | 0 |
| Asthma | 7 | 9 | 16 |
| Chronic Kidney Disease | 0 | 0 | 0 |
| Chronic Obstructive Pulmonary Disorder | 0 | 2 | 2 |
| Liver Disease | 0 | 0 | 0 |
| Cancer | 0 | 1 | 1 |
| Immunodeficiency | 0 | 0 | 0 |
| Other Variables(Participants) | Treatment | Control | Total |
|---|---|---|---|
| Smoking History | 7 | 8 | 15 |
| Symptoms at Testing | 38 | 36 | 74 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2021 to primary completion in May 2022, 9 months.
Results were first posted in Sep 2024, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cholecalciferol · Ascorbic Acid · Zinc · Vitamin K 2
The Canadian College of Naturopathic Medicine